Inotiv Inc
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more
Inotiv Inc (NOTV) - Net Assets
Latest net assets as of December 2025: $109.02 Million USD
Based on the latest financial reports, Inotiv Inc (NOTV) has net assets worth $109.02 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($734.34 Million) and total liabilities ($625.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $109.02 Million |
| % of Total Assets | 14.85% |
| Annual Growth Rate | 11.24% |
| 5-Year Change | 29.39% |
| 10-Year Change | 1723.92% |
| Growth Volatility | 242.93 |
Inotiv Inc - Net Assets Trend (1997–2025)
This chart illustrates how Inotiv Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Inotiv Inc (1997–2025)
The table below shows the annual net assets of Inotiv Inc from 1997 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $136.03 Million | -20.22% |
| 2024-09-30 | $170.50 Million | -36.50% |
| 2023-09-30 | $268.49 Million | -25.37% |
| 2022-09-30 | $359.77 Million | +242.22% |
| 2021-09-30 | $105.13 Million | +1283.99% |
| 2020-09-30 | $7.60 Million | -29.08% |
| 2019-09-30 | $10.71 Million | -1.60% |
| 2018-09-30 | $10.88 Million | +28.55% |
| 2017-09-30 | $8.47 Million | +13.53% |
| 2016-09-30 | $7.46 Million | -30.42% |
| 2015-09-30 | $10.72 Million | +12.40% |
| 2014-09-30 | $9.54 Million | +0.81% |
| 2013-09-30 | $9.46 Million | -1.37% |
| 2012-09-30 | $9.59 Million | -38.47% |
| 2011-09-30 | $15.59 Million | +46.11% |
| 2010-09-30 | $10.67 Million | -18.70% |
| 2009-09-30 | $13.12 Million | -26.27% |
| 2008-09-30 | $17.80 Million | -4.09% |
| 2007-09-30 | $18.55 Million | +6.92% |
| 2006-09-30 | $17.35 Million | -11.45% |
| 2005-09-30 | $19.60 Million | +0.92% |
| 2004-09-30 | $19.42 Million | -1.55% |
| 2003-09-30 | $19.73 Million | +4.38% |
| 2002-09-30 | $18.90 Million | +5.99% |
| 2001-09-30 | $17.83 Million | +11.01% |
| 2000-09-30 | $16.06 Million | -7.69% |
| 1999-09-30 | $17.40 Million | +3.57% |
| 1998-09-30 | $16.80 Million | +143.48% |
| 1997-09-30 | $6.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inotiv Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12716.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.55 Million | 6.29% |
| Other Comprehensive Income | $2.23 Million | 1.64% |
| Other Components | $756.06 Million | 555.81% |
| Total Equity | $136.03 Million | 100.00% |
Inotiv Inc Competitors by Market Cap
The table below lists competitors of Inotiv Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sub Sri Thai Real Estate Investment Trust
BK:SSTRT
|
$12.21 Million |
|
GNCO Co. Ltd
KQ:065060
|
$12.21 Million |
|
Zakłady Lentex SA
WAR:LTX
|
$12.22 Million |
|
ABO-Group Environment N.V.
LSE:0QXA
|
$12.22 Million |
|
AMIGO HLDGS PLC. LS-0025
F:0VG
|
$12.21 Million |
|
Tander Inversiones SOCIMI SA
MC:YTAN
|
$12.20 Million |
|
Oriental Carbon & Chemicals Limited
NSE:OCCL
|
$12.20 Million |
|
JOY SPREADER GROUP INC.
F:5YN
|
$12.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inotiv Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 170,504,000 to 136,028,000, a change of -34,476,000 (-20.2%).
- Net loss of 68,625,000 reduced equity.
- New share issuances of 27,524,000 increased equity.
- Other comprehensive income increased equity by 816,000.
- Other factors increased equity by 5,809,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.62 Million | -50.45% |
| Share Issuances | $27.52 Million | +20.23% |
| Other Comprehensive Income | $816.00K | +0.6% |
| Other Changes | $5.81 Million | +4.27% |
| Total Change | $- | -20.22% |
Book Value vs Market Value Analysis
This analysis compares Inotiv Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.24x to 0.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-09-30 | $1.57 | $0.38 | x |
| 1998-09-30 | $3.82 | $0.38 | x |
| 1999-09-30 | $3.72 | $0.38 | x |
| 2000-09-30 | $3.53 | $0.38 | x |
| 2001-09-30 | $3.88 | $0.38 | x |
| 2002-09-30 | $4.09 | $0.38 | x |
| 2003-09-30 | $4.22 | $0.38 | x |
| 2004-09-30 | $4.00 | $0.38 | x |
| 2005-09-30 | $4.02 | $0.38 | x |
| 2006-09-30 | $3.55 | $0.38 | x |
| 2007-09-30 | $3.74 | $0.38 | x |
| 2008-09-30 | $3.58 | $0.38 | x |
| 2009-09-30 | $2.67 | $0.38 | x |
| 2010-09-30 | $2.17 | $0.38 | x |
| 2011-09-30 | $2.75 | $0.38 | x |
| 2012-09-30 | $1.34 | $0.38 | x |
| 2013-09-30 | $1.13 | $0.38 | x |
| 2014-09-30 | $1.20 | $0.38 | x |
| 2015-09-30 | $1.22 | $0.38 | x |
| 2016-09-30 | $0.92 | $0.38 | x |
| 2017-09-30 | $0.97 | $0.38 | x |
| 2018-09-30 | $1.24 | $0.38 | x |
| 2019-09-30 | $1.03 | $0.38 | x |
| 2020-09-30 | $0.70 | $0.38 | x |
| 2021-09-30 | $7.58 | $0.38 | x |
| 2022-09-30 | $14.80 | $0.38 | x |
| 2023-09-30 | $10.50 | $0.38 | x |
| 2024-09-30 | $6.58 | $0.38 | x |
| 2025-09-30 | $4.19 | $0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inotiv Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.38%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 5.67x
- Recent ROE (-50.45%) is below the historical average (-15.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 10.14% | 4.70% | 0.94x | 2.30x | $10.00K |
| 1998 | 2.38% | 2.20% | 0.82x | 1.33x | $-1.28 Million |
| 1999 | 3.45% | 3.02% | 0.76x | 1.51x | $-1.14 Million |
| 2000 | -8.60% | -7.19% | 0.72x | 1.66x | $-2.99 Million |
| 2001 | 9.91% | 6.99% | 0.90x | 1.57x | $-16.28K |
| 2002 | 5.64% | 4.02% | 0.79x | 1.77x | $-823.39K |
| 2003 | 0.44% | 0.29% | 0.66x | 2.28x | $-1.89 Million |
| 2004 | -1.05% | -0.55% | 0.79x | 2.41x | $-2.15 Million |
| 2005 | -0.52% | -0.24% | 0.89x | 2.44x | $-2.06 Million |
| 2006 | -15.04% | -6.06% | 1.02x | 2.44x | $-4.35 Million |
| 2007 | 4.99% | 2.05% | 1.08x | 2.27x | $-929.40K |
| 2008 | -8.37% | -3.57% | 1.03x | 2.27x | $-3.27 Million |
| 2009 | -41.64% | -17.19% | 0.98x | 2.48x | $-6.78 Million |
| 2010 | -25.23% | -9.35% | 0.97x | 2.79x | $-3.76 Million |
| 2011 | 3.48% | 1.64% | 1.02x | 2.08x | $-1.02 Million |
| 2012 | -66.63% | -22.65% | 1.05x | 2.81x | $-7.35 Million |
| 2013 | 8.17% | 3.50% | 0.86x | 2.71x | $-172.90K |
| 2014 | -11.22% | -4.35% | 1.03x | 2.49x | $-2.02 Million |
| 2015 | 10.16% | 4.80% | 0.95x | 2.22x | $17.20K |
| 2016 | -43.31% | -15.80% | 0.97x | 2.83x | $-3.98 Million |
| 2017 | 10.44% | 3.65% | 1.19x | 2.41x | $37.30K |
| 2018 | -1.78% | -0.74% | 0.84x | 2.87x | $-1.28 Million |
| 2019 | -7.38% | -1.81% | 1.04x | 3.92x | $-1.86 Million |
| 2020 | -61.68% | -7.75% | 0.98x | 8.11x | $-5.44 Million |
| 2021 | 10.36% | 12.16% | 0.28x | 3.06x | $382.20K |
| 2022 | -93.59% | -61.58% | 0.57x | 2.67x | $-373.30 Million |
| 2023 | -39.06% | -18.37% | 0.67x | 3.18x | $-132.06 Million |
| 2024 | -63.60% | -22.10% | 0.63x | 4.58x | $-125.50 Million |
| 2025 | -50.45% | -13.38% | 0.67x | 5.67x | $-82.23 Million |
Industry Comparison
This section compares Inotiv Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inotiv Inc (NOTV) | $109.02 Million | 10.14% | 5.74x | $12.21 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |